The Leukemia & Lymphoma Society, Inc.

The Leukemia & Lymphoma Society, Inc.

The Leukemia & Lymphoma Society, Inc.

Date Founded



3 International Drive, Suite 200, Rye Brook, NY, 10573, USA

Charitable Causes

Cancer Research

Employees (Worldwide)



Other Business & Consulting Services
Market & Policy Research

Company Description

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services.  Founded in 1949, it is relentless in pursuit of its mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

Contact Data
Trying to get in touch with decision makers at The Leukemia & Lymphoma Society, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Administrative Officer & Chief Financial Officer

Chief Development Officer

Chief Product Officer

Chief of Staff

Benefit Plan Administrator

Senior Vice President Chief

Vice President App & Tra

Executive Director

Executive Director

Board of Directors

Former Chief Executive Officer of United States & Managing Director, North America at Accenture LLP

Chief Marketing Officer & Executive Vice President at Burlington Coat Factory Investments Holdings, Inc.

Chair, Department of Hematology at Mayo Clinic

Head of Corporate Social Responsibility & Global Diversity & Inclusion at Northern Trust Corporation

Provost & Chief Scientific Officer at City of Hope - California

Founder at Boston Millennia Partners

Former Managing Director at Pacific Investment Management Co. LLC

Former Partner, Transaction Advisory Services at Ernst & Young LLP

Founder at M2Gen Corp.

Co-Founder at Start Smart Career Center

Paths to The Leukemia & Lymphoma Society, Inc.
Potential Connections via
Relationship Science
The Leukemia & Lymphoma Society, Inc.
Advisors & Consultants

Chair, Department of Hematology at Mayo Clinic


Contributing Writer at CancerForward


Assistant Professor, Department of Population Sciences at City of Hope - California


Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Key Stats and Financials As of 2017
Market Capitalization
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Political Donations
Details Hidden

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

Affimed NV Medical Support Services | Heidelberg, BW

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Stemline Therapeutics, Inc. Medical Support Services | New York, NY

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Kite Pharma, Inc. Medical Support Services | SANTA MONICA , CA

Kite Pharma, Inc. engages in the development and commercialization of novel cancer immunotherapy products. It offers chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam in June 2009 and is headquartered in Santa Monica, CA.

Awards & Honors
Rank #55
NonProfit Times - Top 100
Sponsored by The NonProfit Times
Rank #52
NonProfit Times - Top 100
Sponsored by The NonProfit Times
Rank #51
NonProfit Times - Top 100
Sponsored by The NonProfit Times
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by The Leukemia & Lymphoma Society, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of The Leukemia & Lymphoma Society, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and The Leukemia & Lymphoma Society, Inc..